Qiagen NV

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics Saw Positive Results from GeneSight Trial

    Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics’ GeneSight: A Major Growth Driver in 2018?

    In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BRACAnalysis CDx Received FDA Approval for Ovarian Cancer Indication

    On March 27, 2017, the FDA also approved BRACAnalysis CDX test as a complementary diagnostic test to be used with ovarian cancer maintenance therapy Tesaro’s (TSRO) Zejula (miraparib).

    By Margaret Patrick
  • uploads/uploads///Vanguard Capital Opportunity Fund %E%% Investor Shares Vs Peers
    Company & Industry Overviews

    Options for Investors in the Vanguard Capital Opportunity Fund

    From a purely NAV (net asset value) return standpoint, the Vanguard Capital Opportunity Fund has had a forgettable one-year period until March 18, 2016, as it stood tenth among its peer group.

    By David Ashworth
  • uploads///Graph Part
    Company & Industry Overviews

    Dyax Traded above Its 100-Day Moving Average

    Dyax (DYAX) gained 9.41% last week. The stock went up after Dyax presented at the Morgan Stanley global healthcare conference, which took place September 16-18 in New York.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.